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Abbreviations   
 
ABS American brachytherapy society  
BED Biological effective dose 
CT Computed tomography  
DVH Dose volume histogram 
EBRT External beam radiotherapy 
EQD2 Equivalent dose in 2 Gy per fraction  
EUS Endoscopic ultrasound 
FDG 18F-fluoro-deoxy-D-glucose 
FRFSE Fast recovery fast spin echo 
HDR High-dose rate  
IR FSE Inversion recovery fast spin echo 
LDR Low-dose rate  
MDR Medium-dose rate  
MR Magnetic resonance 
OAR Organ at risk 
PDR Pulsed-dose rate 
PET  Positron emission tomography 
PTV Planning target volume 
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Popular scientific summary in Swedish 
 
Strålbehandling är en vanlig behandlingsteknik för behandling av cancer. 
Behandlingen kan levereras på två olika sätt: internt eller externt. Vid extern 
strålbehandling bestrålas tumören med en strålkälla som befinner sig utanför 
kroppen. Vid intern strålbehandling, även kallat brachybehandling, placeras 
strålkällan inuti kroppen, i eller i nära anslutning till tumören. Själva tumören får 
därmed mycket strålning samtidigt som omkringliggande vävnad skonas.  
  
Vid brachybehandling av cancer i matstrupen förs en radioaktiv strålkälla ner i 
matstrupen genom en sond. Strålkällan stannar i ett antal bestämda positioner till 
dess att tumören mottagit den dos läkaren har ordinerat. Dagens 
behandlingsplaner utförs på en röntgenbild med hjälp av markörer som markerar 
tumörens utsträckning. På grund av otillräcklig information i röntgenbilden kan 
inte tumörens volym bestämmas, vilket kan medföra att tumören erhåller felaktig 
dos. 
 
Information om tumörens volym kan däremot fås genom tredimensionella bilder 
från en magnetisk resonanstomografi (MR) kamera. Dessa bilder ger möjligheten 
att urskilja olika vävnader i kroppen, vilket gör det lättare att separera tumören 
från omkringliggande vävnad.   
  
Syftet med projektet är att utforma en behandlingsmetod för cancer i matstrupen 
med MR som bildunderlag vid planering av behandling. Vid avbildning av 
matstrupen uppstår tekniska utmaningar då både hjärtats aktivitet och 
andningsrörelser bidrar till störningar i MR-bilder. Ett MR protokoll har 
utarbetas under denna studie och en tumör i matstrupen hos en patient har kunnat 
avbildas med tillräckligt god bildkvalité för att kunna användas som underlag för 
behandling.  
  
 
 	  
	  
Abstract 
 
Purpose: The aim of this study was to investigate a new methodology for 
brachytherapy of oesophageal cancer using magnetic resonance (MR) imaging 
for treatment planning. That includes finding a suitable oesophageal applicator 
that can be visualised on MR images and to create dose and fraction schedule 
that should be used brachytherapy treatments.  
 
Material and Methods: A total of six patients were involved to determine a 
suitable MR sequence for visualisation of the oesophageal tumour. The patients 
were scanned with two different T2-weighted sequences, inversion recovery fast 
spin echo (IR FSE) and fast recovery fast spin echo (FRFSE). The imaging was 
performed on a 3.0 T MR scanner from GE Healthcare. Dose planning was 
performed on MR images using two different methods. In the first method the 
dose was prescribed at 10 mm from the applicator centre, as currently used at 
Skåne University Hospital. In the second method the dose planning was 
performed by manually adjusting the dwell times until tumour coverage was 
reached. An MR safe oesophageal applicator could not be found on the market. 
Therefore a duodenal tube was used and modified. Different contrast agents were 
studied in order to render the tube visible on MR images. 
 
Results: The oesophageal tumour was successfully visualised and delineated on 
T2-weighted images with FRFSE sequences. Furthermore, improved dose 
coverage to the tumour was observed when the dose planning was manually 
optimised to the tumour volume, where V100% to the tumour was increased from 
70% to 95%. Moreover, the applicator was filled with a saline solution and was 
visualised on the MR images.  
 
Conclusion: Brachytherapy treatment for oesophageal cancer with MR imaging 
provides an improved tumour visualisation and the manifesting of DVH 
parameters enables dose coverage to the tumour.  
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1. Introduction 
1.1 Background 
 
Cancer of the oesophagus is the ninth most common carcinoma worldwide and 
has a high cancer-related mortality (Pennathur et al., 2013, Torre et al., 2015). 
The most common symptoms of oesophageal cancer, dysphagia and weight loss, 
arise first when the carcinoma has reached an advanced stage, hence the poor 
prognosis. A good outcome of the carcinoma is associated with early stage 
diagnosis. Oesophageal cancer has a 5-year overall survival rate with less than 20 
% of survival, making it one of the lowest long-time survival rates among 
different cancer diagnoses (Pennathur et al., 2013, Hujala et al., 2002).  
  
The primary curative approach of oesophageal cancer is radical surgery, however 
about 60-70% of the patients are not suitable to undergo the procedure due to 
unfavourable diagnosis, i.e. the cancer has progressed into an inoperable stage. 
Heavy alcohol intake and long-time smoking are often associated with the 
carcinoma, consequentially contributing to poor health conditions making 
surgery impractical (Fabrini et al., 2010, Pennathur et al., 2013). When surgery is 
not possible, external beam radiotherapy (EBRT) with or without concurrent 
chemotherapy is another treatment approach. Intraluminal brachytherapy is also 
preferred as a boost following EBRT (Muijs et al., 2012, Murakami et al., 2012).  
 
The main purpose with palliation treatment of oesophageal cancer is dysphagia 
relief (Hujala et al., 2002). A variety of modalities are used for treatment, such as 
external radiation therapy and/or intraluminal brachytherapy, oesophageal 
stenting and laser procedures (Hujala et al., 2002, Lettmaier and Strnad, 2014). 
The two latter therapies have presented a more rapid relief in dysphagia 
compered to intraluminal brachytherapy. However, intraluminal brachytherapy 
provides a more long-lasting effect and should be used for patients with longer 
life expectancies (Bergquist et al., 2005, Homs et al., 2004). Intraluminal 
brachytherapy has the advantage of delivering high doses to the target volume 
and low doses to surrounding normal tissue. This is considered as an advantage 
when intraluminal brachytherapy is used as a boost to EBRT, since the window 
for additional radiation exposure to critical organs such as the spinal cord after 
EBRT is small (Folkert et al., 2013).  
 
Because of the adjacent radiosensitive organs, i.e. organs at risk (OAR), an 
accurate dose planning is essential. Dose planning is currently performed with x-
ray imaging combined with the information from endoscopy for brachytherapy. 
The treatment trajectory is based on two-dimensional (2D) images, which lack 
the ability to provide information regarding the volume of the tumour. 
Furthermore, due to treatment uncertainties, additional longitudinal margins are 
added to the tumour. By introducing three-dimensional (3D) images, the margins 
of the tumour’s delineation can be decreased. Additionally, 3D-images provide 
dose volume information of the tumour and the OARs (Potter et al., 2006). 
 
Magnetic resonance (MR) imaging provides a great soft-tissue contrast and is a 
non-invasive technique. The utility of MR in dose planning has been seen in 
malignancies in other sites, such as cervix and prostate cancer (Groenendaal et 
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al., 2012, Dimopoulos et al., 2012). To this stage, the evidence of MR for dose 
planning and tumour delineation for oesophageal cancer is limited, but the idea is 
promising (van Rossum et al., 2015).  
1.2 Aim 
 
The purpose of this study is to evaluate a method for treating oesophageal cancer 
with brachytherapy using MR-imaging. This includes evaluating the imaging 
modality for dose planning, creating a dose and fraction schedule, as well as 
finding a suitable applicator. Ultimately, this method will be implemented at 
Skåne University Hospital in Lund, Sweden.  
2. Theory  
2.1 Anatomy of the oesophagus 	  The oesophagus is a hollow muscular tube with a length of 25 to 30 cm with a 
diameter of 2 cm, connecting the pharynx with the stomach. The oesophagus 
runs in front of the spinal cord, traverses through the diaphragm and runs behind 
the trachea and heart. The oesophagus is anatomically divided into three distinct 
regions: cervical, thoracic and abdominal oesophagus (Figure 1) (American 
Cancer Society, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The anatomy of the oesophagus (http://www.seattlecca.org/client/Esophagus-large.jpg). 
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The oesophageal wall is composed of four layers: mucosa, submucosa, 
muscularis propria and adventitia (Figure 2) (Jobe et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mucosa, the innermost layer is composed of three sublayers. The first 
sublayer, the epithelium, covers the inner surface of the oesophagus with a 
stratified non-keratinized squamous epithelium lining. Lamina propria, the 
second sublayer of the mucosa, is a connecting tissue that connects the 
epithelium with the muscularies mucosae, which is the third sublayer. The 
muscularies mucosa consists of a double layer of smooth muscles. The 
submucosa contains loose connective tissue, lymphocytes, plasma cells, nerve 
cells, a vascular network and submucosal glands. The glands secrete mucus to 
support and ease the passage of food through the oesophageal. The thick layer of 
muscularis propria is responsible for the motor function and helps the food to 
pass the oesophagus by rhythmic movements. The adventitia is the outermost 
external layer of the oesophagus and it connects it to neighbouring structures. 
The adventitia is composed of loose connective tissue (Jobe et al., 2009, 
American Cancer Society, 2015). 
 
2.2 Cancer of the oesophagus  
 
Cancer of the oesophagus emerges from the innermost layer, the epithelium, and 
spreads out to the outer layers. Squamous cell carcinoma and adenocarcinoma 
are the two most prevalent histological types of oesophageal cancer, representing 
about 90% of the diagnoses (American Cancer Society, 2015). Other less 
common histological types are melanoma, leiomyosarcoma and small-cell 
carcinoma (Pennathur et al., 2013). The incidence of oesophageal cancer 
increases with age and the risk of getting oesophageal cancer is four times higher 
for men than women (Torre et al., 2015).  
 
Squamous cell carcinoma derives from the squamous dells in the lining of the 
oesophagus. The carcinoma is dominant in developing countries and is prevalent 
in populations of lower socio-economics development. Risk factors associated 
Figure 2. The layers of the oesophageal wall.  
(http://www.cancer.gov/images/cdr/live/CDR752730.jpg) 
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with squamous cell carcinoma are a long-time tobacco use, heavy alcohol intake, 
achalasia and history of head and neck cancer (Pennathur et al., 2013, American 
Cancer Society, 2015). The incidence of squamous cell carcinoma has decreased 
or stayed constant over the last decades. The occurrence is also related to 
ethnicity. For instance, African-Americans are more likely to develop squamous 
cell carcinoma than adenocarcinoma, and the opposite applies for the Caucasian 
population (Jobe et al., 2009). 
 
Adenocarcinoma derives from the gland cells, which usually do not thrive at the 
epithelium lining of the oesophagus. In order for adenocarcinoma to develop 
gland cells must replace the squamous cells. A disease that eliminates squamous 
cells from the epithelium is thus associated with adenocarcinoma. Gastro-
oesophageal reflux disease (GORD) is a condition that occurs when the acid and 
enzymes existing in the stomach aimed to digest the food leak to the lower part 
of the oesophagus. GORD and its associated conditions, such as Barrett’s 
oesophagus have shown to be risk factors to adenocarcinoma. Barrett’s 
oesophageal disease develops after a long time occurrence of GORD, where the 
epithelium of the oesophagus will be damaged and the squamous cells will be 
replaced with gland cells. Adenocarcinoma is therefore more prevalent in the 
lower part of the oesophagus (American Cancer Society, 2015). The carcinoma 
has shown an increased incidence in higher socio-economic classes and obesity. 
Adenocarcinoma is dominated in the western nations, such as North America and 
Western Europe (Jobe et al., 2009). 
 
2.3 Brachytherapy  
 
Brachytherapy is a treatment modality that has been used since the beginning of 
the 20th century. In brachytherapy radioactive source are placed near into a target 
volume.	    Brachytherapy has the ability to deliver high doses to the tumour 
volume and low doses to surrounding normal tissue due to the steep dose 
gradient of the radioactive source (GEC ESTRO Handbook of Brachytherapy, 
2002). 
  
The radiation doses can be delivered interstitial, intracavitary, intraluminal or by 
surface brachytherapy. For interstitial brachytherapy the radioactive source are 
placed into body tissue. This treatment therapy is common for prostate cancer 
where the needles are pierced into the prostate. For intracavitary brachytherapy 
the source are placed in pre-existing body cavities adjacent to the treatment 
volume. Intracavitary therapy is used for gynaecological and nasopharynx 
malignancies (Metcalfe et al., 2007). Treatment of sites such as oesophagus, 
bronchus and biliary duct are referred to as intraluminal brachytherapy. Surface 
brachytherapy is used for skin cancers and soft tissue carcinoma. (GEC ESTRO 
Handbook of Brachytherapy, 2002). 
 
Treatment with brachytherapy can be delivered with different dose rates: 
 
• Low- dose rate (LDR) 0.4-2 Gy/h 
• Medium-dose rate (MDR) 2-12 Gy/h 
• High-dose rate (HDR) >12 Gy/h 
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Low-dose rate brachytherapy is used for both temporary and permanent 
treatments. For temporary treatments the radioactive source is taken out of the 
patient after a period of time. For permanent implants the radioactive sources, 
usually in encapsulated seeds, are to deliver the dose over several months to the 
target volume. In high-dose rate (HDR) brachytherapy, sources with high activity 
are used. In HDR brachytherapy the dose is delivered step by step in 
predetermined positions (dwell points) covering the entire tumour over a course 
of minutes (Metcalfe et al., 2007). In pulsed-dose rate (PDR) the dose is 
delivered in many short exposures, administering the same total dose as for LDR 
treatments. PDR brachytherapy uses thus the physical advantages of HDR 
treatment and the radiobiological advantages of LDR treatment (GEC ESTRO 
Handbook of Brachytherapy, 2002, (Metcalfe et al., 2007). 
 
To deliver the dose, a remote afterloading machine is preferred (Figure 3). The 
afterloading machines have the capability to alter the positions of the source and 
the time in each position (dwell time) corresponding to the predetermined dose 
plan (Metcalfe et al., 2007). The machines have a safe where the radioactive 
source is stored and the source can easily be delivered from the safe to the 
patient. The afterloading machine can be controlled outside the treatment room 
and thus prevent radiation exposure to the staff.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
The radioactive sources are sealed and encapsulated with metal to avoid leakage 
of the isotopes and to absorb beta particles. The most prevalent radioactive 
source used today in HDR brachytherapy is iridium-192 (192Ir), which decays 
through emission of 𝛽 -particles and electron capture (EC). The 𝛽- particles will 
be absorbed in the encapsulated material and not contribute to the dose. The 
average energy of the emitted photons is 370 keV (Metcalfe et al., 2007). The 
decays of 192Ir with a yield greater than 5 % are presented in Table 1.  
 
 
 
 
 
 
 
 
Figure 3. Varian GammaMedplus iX HDR/PDR remote afterloader 
(www.varian.com) 
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Table 1. Decays of 192Ir with a yield greater than 5 % 
(http://www.nndc.bnl.gov/useroutput/192ir_mird.html). 
Decay Yield (%) Energy (keV) 𝛽! 41.4 162 𝛽! 48.0 210 𝛽! 5.60 71,6 𝛾 28.7 296 𝛾 29.7 309 𝛾 82.7 317 𝛾 47.8 468 𝛾 8.20 604 𝛾 5.34 613 𝛾 8.00 7.24 
 	  
2.4 Brachytherapy of oesophageal cancer  
 2.4.1 Curative treatment  	  
Brachytherapy is given both as a sole treatment modality and as a boost 
following external beam radiotherapy for curative treatments. Data from 
brachytherapy as a sole treatment modality is limited and the therapy is preferred 
for very early stages of the carcinoma (Lettmaier and Strnad, 2014). 
Brachytherapy is predominantly used as a boost following external beam 
radiotherapy with or without concomitant chemotherapy. A higher survival rate 
is obtained with concomitant chemotherapy for patients in general good health 
conditions (Gaspar et al., 1997). Chemotherapy is contraindicated for patients 
with poor health conditions due to the high toxicities and patients should be 
evaluated if they are appropriate candidates to receive chemotherapy.   
 
The American Brachytherapy Society (ABS) (1997) has published consensus 
guidelines for brachytherapy of cancer in the oesophagus. The guidelines include 
recommendations for patient selection and dose and fractional schedule for 
curative treatment with intraluminal brachytherapy (Table 2). For patients 
receiving external beam radiotherapy with concurrent chemotherapy, an external 
dose of 45-50 Gy, in fractions of 1.8-2.0 Gy, is given. For patients unable to 
receive chemotherapy, the dose is increased to 60 Gy. Intraluminal 
brachytherapy is recommended to begin 1-3 weeks after external radiotherapy in 
order for the acute reactions to subside.      
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Table 2. Guidelines for dose recommendations and patient selection for curative intraluminal brachytherapy 
treatment of oesophageal cancer.  
Good candidates 
Unifocal squamous or adenocarcinoma of the thoracic oesophagus 
Length of primary tumour ≤10 cm  
No regional lymph node or metastatic disease 
Contraindications 
Oesophageal fistula 
Cervical oesophageal location 
Stenosis that cannot be bypassed 
Dose recommendations (After 45-60 Gy EBRT) 
HDR 10 Gy, 5 Gy/fraction over two weeks* 
* The doses should be prescribed 1 cm from the midsource or mid-well position.   
 
Newer consensus guidelines for brachytherapy of oesophageal cancer have yet to 
be published. A few studies have implemented different doses and fraction 
schedules for curative treatment of oesophageal cancer (Table 3).  
 
Muijs et al. (2012) analysed a study where external beam radiotherapy in 
combination with intraluminal brachytherapy was used to treat oesophageal 
cancer. Eligible patients for this study were patients with tumour stage T1-4 N0-
1 M1a without distant metastasis and patients with a tumour length ≤ 6 cm. 
However, after 2005 the tumour length criteria were excluded. The 
brachytherapy was delivered one week before and one week after the external 
beam radiotherapy treatment. The dose was prescribed 10 mm from the centre of 
the applicator and an applicator with an outer diameter of 6 mm was used. Severe 
toxicities such as acute bleeding, stricture and ulcers occurred in 10 patients 
(16%). The authors concluded that due to a high rate of severe toxicities and the 
high doses to the oesophageal wall, intraluminal brachytherapy should only be 
considered for well-selected patients.   
 
Murakami et al. (2012) presented results from a long-term study of superficial 
oesophageal cancers treated with intraluminal brachytherapy in combination with 
external beam radiotherapy. Patients with thoracic oesophageal cancer were 
eligible for this study. Patients with tumours in the muscularis mucosa or a 
deeper invasion were given intraluminal brachytherapy as a boost following 
external beam radiotherapy. Brachytherapy was given five times a week and was 
performed immediately after completed external beam radiotherapy irradiation. 
The brachytherapy dose was prescribed 5 mm from the applicator surface and the 
diameter of the applicator was 16 or 20 mm. The acute toxicities that occurred 
were esophagitis, leukopenia and thrombocytopenia and late toxicities 
pneumonitis. The authors deduced that the results obtained for treatment of 
submucosal cancer with intraluminal brachytherapy as a boost following external 
beam radiotherapy were not satisfactory and a consideration towards a more 
intensive treatment should be done.  
 
Tamaki et al. (2012) studied intraluminal brachytherapy as a boost following 
external beam radiotherapy for superficial oesophageal cancer. All the patients in 
this study had cancer in the thoracic part of the oesophagus. Low-dose rate 
brachytherapy was delivered to 19 patients and delivered once a week and high-
dose rate brachytherapy was delivered twice a week to the remaining 35 patients. 
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The brachytherapy dose was prescribed 5 mm from the applicator surface and an 
applicator with the diameter 15-20 mm was used. A total of 11 patients (20%) 
had tumour recurrence. The authors encourage the use of HDR as a boost 
following external beam radiotherapy in the curative setting for patients with 
superficial oesophageal cancer.  
 
Gaspar et al. (2000) studied radiation therapy with concurrent chemotherapy for 
localised carcinoma of the oesophagus. The brachytherapy treatment was given 
with concurrent chemotherapy two weeks after completion of external 
irradiation. The HDR brachytherapy was first given as total dose of 15 Gy with a 
weekly fraction dose of 5 Gy but then decreased to a total dose of 10 Gy with the 
same fractional dose. The dose was prescribed 10 mm from the centre of 
applicator and an applicator with an outer diameter of 4-6 mm was used. The 
authors concluded that combining brachytherapy with chemotherapy should be 
closely evaluated due to the high incidence of toxicities.  
 
Table 3. Overview of studies for curative intraluminal brachytherapy as a boost following external beam 
radiotherapy for oesophageal caner. 
Author n EBRT 
dose 
Intraluminal 
brachytherapy dose 
Local 
control 
Complications Overall 
survival 
Muijs et al. 
(2012) 
62 60 Gy 12 Gy (6 
Gy/fraction) 
71% (1y) Esophagitis 
Ulcerations (11%) 
Strictures (16%)  
Severe toxicities 
(10%) 
11% (5y) 
Murakami et 
al. (2012) 
87 50-61 
Gy 
10 Gy  
(2-2.5Gy/fraction) 
 
a49%, b75% 
(5y) 
Acute effects 
(34%) 
Late effects (20%) 
a31%, b84% 
(5y) 
Tamaki et al. 
(2012) 
54 56-60 
Gy 
10 Gy (5 Gy/fraction)c 
9 Gy (3 Gy/ fraction)d 
79% (5y) Late effects (10%) 61% (5y) 
Gaspar et al. 
(2000) 
49 50 Gy 10-15 Gy  
(5 Gy/fraction) 
37% (1y) Fistulas (12%) 
Severe toxicities 
(59%) 
Life-threatening 
(24%) 
49% (1y) 
aSubmucosal cancer and bmucosal cancer  
cDoses with LDR brachytherapy 
dDoses with HDR brachytherapy  
 
2.4.2 Palliative treatment  	  
The main intent with palliation treatment is to improve patients swallowing 
ability and to increase quality of life. A high priority is therefore to use a therapy 
modality with low side effects and low intervention (Bergquist et al., 2005). The 
main modalities advocated for palliative treatments are intraluminal 
brachytherapy, stent placement and laser therapy (Nd:YAG laser and 
photodynamic therapy) (Homs et al., 2005, Lettmaier and Strnad, 2014)  
 
A few studies have been made comparing the efficacy between the different 
treatment modalities. Homs et al. (2004) conducted a multicentre randomised 
trial comparing single dose brachytherapy with stent placement of oesophageal 
cancer. The outcome was that a more instant relief of dysphagia was obtained 
after stent placement compared to single dose intraluminal brachytherapy. 
However, intraluminal brachytherapy provides with a more long lasting effect 
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and is thus preferred for patients with a life expectancy greater than 3 months 
(Figure 4). Furthermore, more complications are associated with stent placement 
than brachytherapy treatment such as stent migration, tumour growth or fistula 
formation. These results were emphasised by a randomised trial performed by 
Bergquist et al. (2005). Laser procedures have also shown an instant 
improvement in swallowing capability but the disadvantage with the procedure is 
the need of frequent repetition because of the continuous growth of the tumour 
and the expensive treatment costs (Sargeant et al., 1992).  
 
Figure	   4.	   Dysphagia	   score	   after	   stent	   placement	   and	   single	   dose	   brachytherapy	   treatment.	   The	  dysphagia	  score	  has	  a	  range	  from	  0	  to	  4	  where	  0	  represents	  normal	  swallowing	  ability	  (no	  dysphagia)	  and	  4	  represents	  complete	  dysphagia	  (Homs	  et	  al.,	  2004).	  	  
Dose recommendation and patient selection from ABS for palliative HDR 
brachytherapy treatment is presented in Table 4. The dose recommendations are 
dependent on previous treatments and life expectancy. ABS encourages 
intraluminal brachytherapy as a boost following external beam radiotherapy for 
patients with a greater life expectancy than 6 months. As for curative treatment 
the HDR brachytherapy is recommended to begin 2-3 weeks after external 
radiotherapy is completed.    
 
Table 4. Guidelines on dose recommendations for palliative intraluminal brachytherapy treatment. 
Candidate for palliative treatment 
Adeno- or squamous cancers of the thoracic oesophagus with distant metastases 
Unresectable local disease progression/recurrence after definitive radiation treatment 
Dose recommendations*  
Short life expectancy or recurrent cancer after EBRT 
HDR – total dose 10-14 Gy, with 1 or 2 fractions 
No previous EBRT 
EBRT - 30-40 Gy, 2-3 Gy/fraction  
HDR – total dose 10-14 Gy, with 1 or 2 fractions  
No previous EBRT and life expectancy > 6 months 
EBRT - 40-50 Gy, with 1.8-2.0 Gy/fraction 
HDR – total dose 10 Gy, 5 Gy/fraction once a week 
* The doses in the table are prescribed 1 cm from the midsource or mid-well position. 
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An overview of palliative treatment results from different studies treating 
oesophageal cancer with intraluminal brachytherapy is summarized (Table 5).  
 
Rosenblatt et al. (2010) conducted a randomised trial of the International Atomic 
Energy Agency to investigate the efficacy of external beam radiotherapy with 
and without intraluminal brachytherapy. The HDR intraluminal brachytherapy 
treatments were given a median of five days apart and prescribed 10 mm from 
the centre of the applicator. The external beam radiotherapy treatment consisting 
of 30 Gy, 3 Gy/fraction began one week after the second brachytherapy 
treatment. No significant difference in overall survival was noticed between the 
two study arms. An improvement in dysphagia relief was observed in the 
combined therapy arm with an absolute benefit of 18% after 200 days 
nonetheless.    
 
Bergquist et al. (2005) presented the results of a randomised controlled clinical 
trial for palliative treatment of advanced cancer in the oesophagus and gastro-
oesophageal junction. Patients eligible for this study were patients with cancer in 
the oesophagus or gastro-oesophageal junction with metastatic disease and with a 
dysphagia score of at least grade 2 (able to drink and eat semisolid food). The 
brachytherapy treatments were delivered in an interval of 1-2 weeks apart and 
prescribed 10 mm from the applicator surface. A clinical relevant improvement 
regarding eating scale, problems with choking and the ability to eat solid and 
semisolid food was observed 3 months after the treatment.  
  
Homs et al. (2004) conducted a multicentre randomised trial with a single dose 
brachytherapy treatment. Dysphagia control, with an improvement of at least one 
dysphagia score, was detected in 73% of the patients after 1 month. Major 
complications after the treatment occurred in 13 (13%) patients, which consisted 
mainly of haemorrhage and fistula formation. The brachytherapy dose was 
prescribed 10 mm from the centre of the applicator. Furthermore, Kulhavy et al. 
(1995) presented in his study that 12-15 Gy is the optimal dose for single HDR 
brachytherapy. 
 
Skowronek et al. (2004) reported results after HDR brachytherapy treatment for 
palliative treatment. The authors also concluded that patients with a higher 
Karnofsky Performance Status, smaller tumour size and a lower clinical stage 
had a longer survival. Complications in form of esophagobronchial fistula 
occurred in 9 patients (10%) during the first 6 months. Furthermore, an 
association between fistula occurrence and low Karnofsky score and tumour size 
was noted. The brachytherapy dose was prescribed at 10 mm from the centre of 
the applicator.  
 
Sur et al. (2002) presented a randomised trial where HDR brachytherapy was 
received with a dose and fraction schedule of 18 Gy, 6 Gy/fraction and 16 Gy, 8 
Gy/fraction. The total dose of 18 Gy was delivered during 5 days, one fractional 
dose every second day and total dose of 16 Gy was delivered during 3 days, one 
fractional dose every second day. The dose was prescribed 10 mm from the 
applicator centre. No significant difference in dysphagia relief, overall survival 
or complications was observed between the two study arms.  
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Table 5. Overview of studies of palliative intraluminal brachytherapy treatment for oesophageal cancer.  
Author n Total dose (fractional 
dose) 
Dysphagia 
improveme
nt, 
(recurrent 
dysphagia) 
Complications Survival 
(median) 
Rosenblatt et al. 
(2010) 
109 
110  
16 Gy (8 Gy/fraction) 
16 Gy (8 Gy/fraction)a 
66.7 %b 
82.7%b 
Fistulae (7%) 
Fistulae (19%) 
Dilation (14%) 
 
188 days  
Bergquist et al. 
(2005) 
31 21 Gy (7 Gy/fraction)  Perforation (6%) 
Fistulae (3%)  
106 days 
Homs et al. (2004) 101  12 Gy  (single fraction) 73% (43%) Major 
complications 
(13%), minor 
complications (8%)  
155 days  
Skowronek et al. 
(2004) 
91 22.5 Gy (7.5 Gy/fraction) (80%) Esophagobronchial 
fistula (10%) 
246 days  
Sur et al. (2002) 120 
112 
16 Gy (8 Gy/fraction) 
18 Gy (6 Gy/fraction) 
?c 
?d 
Strictures 11% 
Fistulae 10% 
207 days 
273 days  
aAdditional external beam radiotherapy 30 Gy, 3 Gy/fraction 
 bOne year dysphagia relief survival 
cThe median dysphagia free survival was 182 days 
dThe median dysphagia free survival was 238 days 
 
2.4.3 Applicator  
 
The diameter of the applicator used for intraluminal brachytherapy of 
oesophageal cancer has a crucial role on the dose distribution to the tissue, 
especially the mucosa. The ABS recommends an applicator with an external 
diameter between 6-10 mm. As above-mentioned, the dose gradient of the 
brachytherapy sources is very steep and a diameter narrower than 6 mm will 
contribute to high doses to the mucosa and possibly fistula developments and 
ulceration. Furthermore, a diameter greater than 10 mm can increase the risk of 
abrasions and perforations of the oesophagus.  
 
2.5 Imaging techniques for dose planning 
 
In current treatments of oesophageal cancer endoscopy combined with planar x-
ray imaging is used to visualise the tumour and treatment trajectory (Figure 5). 
Due to uncertainties in the tumours proximal and distal boarders, a longitudinal 
margin of 20-30 mm is applied in both directions to include possible microscopic 
disease (Gao et al., 2007). In addition to the lack of accuracy in tumour 
delineation, the imaging technique fails to provide any information about the 
tumour volume, which can lead to inadequate coverage of the treatment volume. 
A study performed by Homs et al. (2004) showed that 43% of the patients treated 
with a single dose brachytherapy presented persistent or recurrent dysphagia 
caused by tumour persistence or tumour regrowth. This is most likely due to an 
inadequate coverage of the treatment volume and unwanted dose exposure to 
healthy parts of the oesophagus. Introducing 3D imaging a more accurate dose 
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coverage of the target volume can be obtained. When dose planning with 3D 
images the ordinated dose is prescribed to the target volume and the dose 
coverage of the tumour can be evaluated by the use of dose volume histogram 
(DVH) parameters. Additionally, the dose to the OARs can be evaluated by the 
DVH parameters (Potter et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The conventional imaging technique for 3D dose planning is computer 
tomography (CT). Studies have demonstrated difficulties in to accurately 
distinguish the proximal and distal margins of oesophageal tumours from CT 
images due to the poor soft tissue contrast. A more accurate estimation of the 
longitudinal tumour extent can be obtained from an endoscopic ultrasound (EUS) 
examination, but unfortunately the information obtained from the EUS is 
difficult to translate to CT images (Muijs et al., 2010). Using positron emission 
tomography (PET) with 18F-fluoro-deoxy-D-glucose (FDG) radiotracer 
functional information based on metabolic activity can be obtained. Combining 
the functional information with the anatomical information from a CT the 
visualisation of the tumour may be improved. However, not enough studies have 
been made to implement PET/CT as an imaging technique for oesophageal 
tumour delineation in radiotherapy and further clinical validation is needed 
(Leong et al., 2006, Muijs et al., 2010).    
 
Magnetic resonance (MR) imaging has shown to be useful in delineation of the 
tumour and organs at risk for numerous of clinical sites such as the prostate, 
cervix and head and neck. MR imaging provides a great contrast in soft tissue 
and distinction of tumour and normal tissue. High-resolution T2-weighted MR 
images have shown to provide detailed images of the oesophageal wall and 
surrounding structures (Riddell et al., 2007). However, there are some technical 
difficulties regarding imaging of the oesophagus due to motion artefacts from 
Figure 5. X-ray image used for treatment planning, visualising clips that marks the distal and 
proximal boarders of the tumour (black arrows) and a marker wire that presents the dwell 
positions of the source. External lead skin markers are also visualised in the image (grey 
arrows).  
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blood flow in the aorta and the respiratory and cardiac movements. To reduce 
respiratory motion technical innovations for the compensation of respiratory and 
cardio motions have been introduced (van Rossum et al., 2015, van Rossum et 
al., 2013).  
3. Method and material 	  
3.1 Current treatment methodologies in Scandinavia 
 
To find out which methodologies are used today to treat oesophageal cancer with 
brachytherapy in Scandinavia, a questionnaire was created. The questionnaire 
was sent to five hospitals in Sweden, three in Denmark and one in Norway and 
Finland respectively. The questionnaire was sent through a survey and included 
12 questions (Appendix I).   
 
3.2 MR imaging 
 
The next step was to investigate the possibility to use MR as an imaging 
technique for brachytherapy of oesophageal cancer. The MR imaging was 
performed at the Oncology Department at Skåne University Hospital in Lund on 
a 3.0 T scanner from GE Healthcare, located next-door to the brachytherapy 
treatment room. The imaging part of this study included a total of six patients 
with oesophageal cancer. The first four patients were scanned with T2-weighted 
inversion recovery fast spin echo (IR FSE) sequences but due to poor image 
quality the two latter patients were scanned with a different sequence, T2-
weighted fast recovery fast spin echo (FRFSE) sequences. The oesophagus was 
scanned in the sagittal plane for assessment about the cranio-caudal tumour 
extent and in the axial plane for assessment on tumour depth and ingrowth to 
nearby structure. Furthermore, to compensate for the respiratory motion a 
navigator that tracks the movement of the diaphragm was used. By following the 
movement of the diaphragm, the scanning was triggered when the diaphragm 
was on its end position. CINE scan was performed in the sagittal and axial planes 
for visualisation of the tumours movement. Additionally, the MR-images of 
patient number 5 were compared with the patient’s CT images. An experienced 
radiologist evaluated the obtained images regarding image quality and the ability 
to delineate the tumour. This study was approved by the Regional Ethics Board 
of Lund, Sweden (EPN Lund, Dnr 2013/742). 
 
3.3 Applicator 
 
An oesophageal applicator would be ideal to use since its construction is made 
for brachytherapy of oesophageal cancer. However, after some research, an MR 
safe oesophageal applicator could not be found and a duodenal tube was used as 
an applicator (Figure 6). In order for the chosen duodenal tube to work in this 
setting, some modifications had to be done. Since the tip of the duodenal tube is 
important to be visualised on an MR image, in order to decide dwell positions for 
the radioactive source, the duodenal tube had to be sealed on its distal end. 
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Furthermore, the tube was made out of a plastic material and thus not visualised 
on MR images. In order to make the tube visible in MR images, the tube was as 
filled with contrast agents with different concentration. Measurements were 
performed with a 0%, 2% and 4% concentration of gadolinium (Gd) in a saline 
solution.   
 
 
 
 
 
 
 
 
 
 
3.4. Dose planning  
 
Dose planning on MR images was performed for one patient, patient number 5, 
in BrachyVision (version 13.0, Varian Medical Systems). An oncologist 
delineated the oesophageal tumour and the OARs consisting of the aorta, heart, 
spinal cord and trachea. The dose planning was performed using two methods. In 
the first method, the ordinated dose was prescribed at 10 mm from the applicator 
centre. In the second method, the dose planning was based on manual 
optimisation of the dwell times until adequate dose coverage (approximately 
100%) of the tumour was reached.   
 
The dose to the oesophageal tumour and the OARs was assessed by the use of 
DVH parameters. The dose to the oesophageal tumour was assessed by the 
minimum dose delivered to 90% (D90%) and 98% (D98%) to the tumour volume 
and the volume that received 100% of the ordinated dose (V100%), i.e. 7.5 Gy. 
The dose to the OARs was evaluated by the minimum dose in the most irradiated 
tissue volume, of 2cm3 (D2cc), adjacent to the applicator.   
  
3.5 Dose and fractional schedule 
 
The effective dose for different fractionations schemes were evaluated by 
calculation of the biological effective dose (BED), using  
 BED = 𝑛𝑑 1+ !!/!      (1) 
 
where n is the number of fractions, d is the dose per fraction and the α/β ratio is 
the parameters of  the linear quadratic model of cell survival. 
 
Equivalent dose in 2 Gy per fraction (EQD2) was calculated for the dose and 
fractional schedules mentioned in Table 3 and Table 5 using 
 
Figure	  6.	  Duodenal tube used as an oesophageal applicator with 
a sealed distal end. 
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EQD! = !"#!!   !!/!      (2) 
 
 
where the α/β ratio for the oesophageal tumour was equal to 10. The dose and 
fractional schedule was then decided in consensus with the brachytherapy 
oncologists. 
 
3.6 Clinical test patient 
 
Patient number 6 was scheduled to undergo intraluminal brachytherapy of 
oesophageal cancer during the course of this thesis. Two clips to mark the 
tumour’s macroscopic longitudinal extent were inserted during endoscopy. After 
the endoscopy, the applicator was inserted in the oesophagus through the 
patient’s nose. Prior to the treatment, the applicator was filled with a saline 
solution for visualisation on the MR images. Inside the applicator a bronchial 
catheter was inserted, in where the source wire (radioactive source) will run. To 
be certain that the bronchial catheter is in the bottom of the applicator, the 
catheter was marked when it reached the bottom. The bronchial catheter was cut 
to a length corresponding to the source wire’s length by a so-called length cutter.  
 
The patient then underwent an MR scan for the purpose of visualising the 
applicator in vivo and for further optimisation of the MR sequence. When the 
MR imaging was completed, the patient was transferred to the treatment room to 
receive brachytherapy. A planar x-ray imaging, fluoroscopy, was used for 
treatment planning. The dose planning x-ray image included visualisation of the 
clips and a marker wire that showed the dwell positions of source (Figure 5). 
Longitudinal margins of 20 mm in the proximal and distal direction were added 
and the dose was prescribed at 10 mm from the applicator centre. The patient 
was ordinated a total dose of 22.5 Gy with a weekly fractional dose of 7.5 Gy. 
4. Results 
4.1 Questionnaire  
 
The questionnaire was sent out to 10 hospitals in total and 6 hospitals (60%) 
responded. None of the hospitals used 3D imaging for dose planning of 
oesophageal cancer.  
  
Uppsala University Hospital only treats oesophageal cancer with HDR 
brachytherapy in the palliative setting. High-dose rate brachytherapy is given 
when external beam radiotherapy and concurrent chemotherapy are unfavourable 
or no longer an option. Brachytherapy is consequently used as a sole treatment 
modality. Planar x-ray imaging is used for dose planning and the patients receive 
a total dose of 5-15 Gy, with a weekly fractional dose of 5 Gy.  
 
Sahlgrenska University Hospital also treats patients in the palliative setting with 
HDR brachytherapy, and they also use planar x-ray image for dose planning. 
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Sahlgrenska combines external beam radiotherapy with brachytherapy and an 
EBRT dose of 18-20 Gy with 2 Gy/fraction is given. Brachytherapy is given in 
different dose schedules, where a total dose of 14 Gy, with 7 Gy/fraction is must 
common.  
 
Karolinska University Hospital and Kuopio University Hospital have not treated 
oesophageal cancer with brachytherapy during the last years. However, 
Karolinska University Hospital is currently discussing new routines regarding 
treatment of oesophageal cancer with brachytherapy. Furthermore, neither 
Rigshospitalet in Copenhagen or Västerbotten County Council treat oesophageal 
cancer with brachytherapy.  
 
4.2 MR imaging  
 
The images from the first four patients were not considered to have a good 
enough image quality to be used for dose planning (Figure 7). The high degree of 
motion artefacts made it hard to visualise the tumour. Moreover, the images were 
blurry and the oesophagus tumour was difficult to distinguish from the 
surrounding tissue.  
 
 	  
 
 
 
 	  	  
 
 
 
The MR sequence used for the two latter patients, i.e. the FRFSE sequence, 
provided a better image quality and the tumour could be visualised and outlined 
(Figure 8a). The parameters for the FRFSE sequence are presented in Table 6.  	  
Table 6. Parameters used for MR scans in the sagittal and axial plane. 
Parameters Sagittal plane Axial plane 
Slice thickness 3 mm 3 mm 
Spacing 10 % 0 % 
Pixel size 0.9 mm × 0.9 mm 1 mm × 1mm 
Echo time 102 ms 102 ms 
Parallel imaging 
acceleration factor 3 4 
Frequency encoding 
direction 
Sup/Inf R/L 
Figure	  7. T2-weighted MR image with an IR FRSE sequence. The motion artefacts in the image 
make it difficult to delineate the oesophageal tumour. These images were not used for treatment 
planning.	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The MR and CT images for patient number 5 are shown in Figure 8. The 
radiologist and oncologist concluded that the tumour was more easily delineated 
in the MR images. In the MR images the oesophageal tumour can be more 
clearly distinguished from the mediastinum, i.e. the adjacent tissue. Moreover, 
the residual motion artefacts in the MR image were deemed not to disturb the 
visualisation of the tumour. 
 
 
 
	  
 
 
 
 
 
 
 
   A    B 
 
 
 
 
4.3 Applicator 
 
Measurements with a T2-weighted sequence were performed for different 
concentrations of Gd in a saline solution are presented in Figure 9. The highest 
signal was obtained when no Gd was used in the saline solution (can to the left). 
Since T2-weighted images are used to visualise the oesophagus, a contrast agent 
that reduces the T1-relaxation time was desired. This because a reduced T1-
relaxation time increases the signal in T2-weighted images, hence the use of Gd. 
However, as it appears in the images the contrast also reduces the T2-relaxation 
time and therefore there was no advantage of using Gd in this setting.  
4.4 Dose planning  
 
DVH histogram for the oesophageal tumour for the two different methods to 
perform dose planning is presented in Figure 10. The DVH parameters for the 
oesophageal tumour are presented in Table 7 and for the organs at risk i.e. the 
heart aorta, trachea and spinal cord are presented in Table 8.   
 
Figure 8. The oesophagus tumour (green) delineated on an MR image (A) and on a CT image 
(B). In the MR image the OARs have been delineated, aorta (pink), spinal cord (yellow) and 
the trachea (blue).   
	  
Figure 9. Measurements with different concentrations of Gd in a saline 
solution; 0% Gd to the left, 2% Gd in the middle and 4% Gd to the right. 
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Figure 9. The dose-volume histogram for the oesophageal tumour when the dose is prescribed at 10 mm 
from the applicator centre (black line) and when the dose planning is performed manually, i.e. until dose 
coverage was reached to approximately 100% of the tumour (green line). 	  
Table 7. Dose-volume histogram parameter for the tumour when dose planning is performed with different 
two methods.  	   D98%	   D90%	   V100%	  
Dose prescribed 
at 10 mm from 
the applicator 
centre	  
4.3 Gy	   5.6 Gy	   70 %	  
Manual dose 
planning	   6.9 Gy	   8.5 Gy	   95%	  
 
 
Table 8. The dose to 2 cm3 of the risk organs when dose planning is performed with two different methods.  
 Aorta Heart Spinal cord Trachea 
Dose prescribed 
at 10 mm from 
the applicator 
centre 
4.8 Gy 3.7 Gy 1.4 Gy 4.6 Gy 
Manual dose 
planning 
6.9 Gy 5.0 Gy 2.0 Gy 7.3 Gy 
 
 
Sagittal and transversal images for the two dose planning methods are shown in 
Figure 11 and Figure 12. The blue line in the figures represents the planning 
target volume (PTV) and the white dotted line in Figure 11 shows the slice of the 
transversal images. A difference in the dose distribution between the two dose 
planning methods can be visualised in Figure 11, where improved dose coverage 
to the PTV is obtained when the dose planning is performed manually. The 
cutoff of the PTV in the images is a consequence due to inadequate scanning of 
the tumour in the transversal plane, where the oncologist outlined the tumour. In 
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the transversal images an improved dose coverage to the PTV for manual dose 
planning can also be visualised.  
 
 
  
 
 	  	  	  	   	  	  	  	  
 
  
Figure 10. Sagittal isodose images where the dose is prescribed at 10 mm from the applicator centre  
(left image) and where the dose planning is performed manually (right image).  The blue line presents the PTV 
and improved dose coverage to the PTV is obtained when the dose planning is performed manually. The white 
dotted line shows the slice of the transversal image in Figure 12.  
Figure 11. Transversal isodose images where the dose is prescribed at 10 mm from the applicator centre (left 
image) and where the dose planning is performed manually (right image). The ordinated dose at 7.5 Gy is shown 
in yellow and the PTV in blue. 	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The dose as a function of the distance for the two dose planning methods for a 
representative slice is shown in Figure 13. The dose at the applicator surface for 
an applicator with the outer diameter of 6 mm is 26 Gy when the dose is 
prescribed at 10 mm from the applicator centre. Furthermore, when the dose 
planning is performed by manual optimisation of the dwell times the dose at the 
applicator surface is 39 Gy. In the case of the clinical test patient, an applicator 
with an outer diameter of 4.7 mm will result in an applicator surface dose of 34 
Gy and 58 Gy, respectively.  	  	  	  
	  
 
 
 
 	  
 
 
 
 
4.5 Dose and fractional schedule 
	  
The calculated EQD2 and the point where the dose was prescribed are presented 
in Table 9 and Table 10 for curative and palliative treatments, respectively. The 
outer diameter of the applicator for the curative treatment is presented in Table 9.  
  
Table 9. The EQD2 dose for the different dose and fractional schedules presented in Table 3. 
Author EQD2 Dose prescription Outer diameter of the 
applicator  
Muijs et al. (2012) 76 Gy 10 mm from the applicator centre 6 mm 
Murakami et al. 
(2012) 70 Gy 
5 mm from the 
applicator surface 16-20 mm 
Tamaki et al. (2012) 73 Gy
a 
70 Gyb 
5 mm from the 
applicator surface 15-20 mm 
Gaspar et al. (2000) 69 Gy 10 mm from the applicator centre 4-6 mm 
aLDR brachytherapy 
bHDR brachytherapy  
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Figure	  13. The dose as a function of the distance for two different ways of dose 
planning: when the dose is prescribed at 10 mm from the applicator centre and when 
the dose is manually optimised by adjusting the dwell times until tumour coverage is 
reached.	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Table 10. The EQD2 dose for the different dose and fractional schedules presented in Table 5. 
Author	   EQD2	   Dose prescription	  
Rosenblatt et al. (2010)	   57 Gy 
24 Gy	   10 mm from the applicator centre	  
Bergquist et al. (2005)	   30 Gy	    10 mm from the applicator surface	  
Homs et al. (2004)	   11 Gy	   10 mm from the applicator centre	  
Skowronek et al. (2004)	   33 Gy	   10 mm from the applicator centre	  
Sur et al. (2002)	   24 Gy 
24 Gy	   10 mm from the applicator centre	  
 
Based on the results from Table 9 and Table 10 the dose and fractional schedule 
that will be used at our clinic is the following: 
 
• For curative treatments, HDR intraluminal brachytherapy will be 
delivered as a boost following external beam radiotherapy. The external 
beam radiotherapy dose of 50-60 Gy will be given in 2 Gy fractions, five 
times per week, followed by a brachytherapy dose of 10 Gy with a 
weekly fractional dose of 5 Gy. The total EQD2 is 63-73 Gy.   
 
• For palliative treatments, HDR intraluminal brachytherapy will be 
delivered as a sole treatment modality. For patients with a longer life 
expectancy, a total dose of 22.5 Gy with a weekly fractional dose of 7.5 
Gy will be given (EQD2 = 33 Gy). However, for patients with shorter life 
expectancy, a single dose of 10 Gy will be given (EQD2 =17 Gy), which 
can be repeated once or twice if necessary.  	  
4.6. Clinical test patient 
 
The MR images from the patient that underwent intraluminal brachytherapy for 
oesophageal cancer are presented in Figure 14. The oesophageal tumour could be 
visualised in the images, but there were some difficulties in determining the 
tumours proximal and distal boarders due to the motion artefacts in the image. 
No dose planning was performed on these images. For this patient an applicator 
with an outer diameter of 4.7 mm was used due to the patient’s narrow lumen 
and the applicator was visualised on a transversal image. Furthermore, the 
diameter of the bronchial catheter was 1.67 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure	  12. T2- weighted MR image with the applicator in vivo 
(white arrow).	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5.	  Discussion	  
5.1 MR imaging 
  
MR imaging of oesophageal cancer has over last years provided a poor imaging 
quality due to motion artefacts (van Rossum et al., 2013). To reduce the motion 
artefacts, faster sequences with cardiac and respiratory gating have been 
recommended (van Rossum et al., 2015). In this study a T2-weighted gated 
FRFSE was used to visualise the oesophageal tumour. The sequence provided a 
good image quality making it possible to delineate the oesophageal tumour. 
However, one limitation with this sequence is that the image quality is strongly 
dependent on the navigator that triggers the scanning. For the navigator to 
achieve its function, the patients must have a respiration with deep breathing and 
a stable respiratory cycle. The effect on the image quality for patients unable to 
fulfil these criteria can be seen in Figure 14. The patient was breathing very 
superficially, with difficulties to take deep breaths, hence the motion artefacts. 
The need of a stable respiratory cycle and a respiration with deep breathing could 
become a problem since the majority of patients receiving brachytherapy due to 
oesophageal cancer, will be in the palliative setting. These patients are therefore 
usually in a poor health condition and difficulties in deep breathing may occur. 
One way to get around this is by instructing the patients when to inhale and 
exhale while they are lying in the MR camera. Additionally, prior to the 
scanning, the patient could receive breathing training. Furthermore, since the MR 
sequence has been performed on two patients, a larger sample is needed for 
further optimisation of the MR sequence.  
 
Accurate tumour delineation is essential for optimisation of the treatment 
planning. The ability to distinguish the oesophageal tumour from surrounding 
tissue is therefore of high importance. The great soft tissue contrast MR imaging 
provides makes it desirable for dose planning. Achieving accurate tumour 
delineation may provide an improvement in local control and less treatment 
related toxicities, which will ultimately lead to better treatment results and a 
better quality of life (van Rossum et al., 2015).  
 
When dose planning is performed manually, an increased dose to the adjacent 
organs may be obtained as a consequence due to improved dose coverage to the 
tumour volume (Table 7 and Table 8). Moreover, the dose to adjacent organs is 
highly dependent on the size and location of the tumour. The advantage with MR 
based brachytherapy is the ability to evaluate the dose to the organs at risk and 
the tumour volume by DVH parameters. However, no DVH recommendations or 
constraints for the organs at risk or the oesophageal tumour have been found in 
the literature.    
 
Uncertainties that can occur in the MR images are susceptibility artefacts, which 
arise in areas between air and tissue, along with geometric distortion due to 
nonlinearities. By increasing the frequency bandwidth in the images, the 
susceptibility artefacts can be reduced. Moreover, geometric distortion due to 
nonlinearities in the gradient system is mainly associated with the greater field of 
views. For scanning of the oesophagus the average value of the geometric 
distortion is less than 1 mm, according to phantom measurements performed on 
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the 3.0 T MR-camera. In general, geometric distortion due to nonlinearities leads 
to pixel shifts and intensity variations on MR images. In this study the geometric 
distortion on the reconstruction of the applicator has not been investigated, focus 
was put on the visibility of the applicator.  
 
5.2 Applicator 
 
The applicator has a crucial role in the determination of the accuracy of dose 
delivery. The dose of the radioactive source decreases with the inverse square of 
the distance, and high doses to the mucosal can be reached (Figure 13). Since 
treatment-related complications are associated with high mucosal doses the 
diameter of the applicator has an important role (Folkert et al., 2013). In the 
curative setting, a diameter of at least 10 mm is recommended (GEC ESTRO 
Handbook of Brachytherapy, 2002). However, in the palliative setting the 
diameter of the applicator is dependent on the patient’s lumen and sometimes an 
applicator with a diameter less than the recommendations must be used. 
Moreover, the late complications are not of importance for palliative treatments.  
 
Another aspect that requires attention is the centration of the source wire in the 
oesophageal applicator, which is a limitation with the applicator introduced in 
this study. The bronchial catheter will help with the centration of the source wire 
since it will transverse the catheter. However, the bronchial catheter also has the 
ability to move radially in the duodenal tube. The degree of movement is 
dependent on the diameter of the duodenal tube, where the radial movement 
increases with the size of the duodenal tube. For patient 6 in this study, the inner 
diameter of the duodenal tube that was used was 3.5 mm and the bronchial 
catheter with an outer diameter of 1.67 mm could theoretically move 1.83 mm 
radially.  
 
 Oesophageal applicators on the market today have the possibility to centre the 
source wire, but the applicators found are not MR safe. Manufacturing MR safe 
oesophageal applicators would improve the accuracy of dose delivery. 
5.3 Dose planning  
 
The two-dimensional imaging technique that is used for dose planning today fails 
to provide any information about the tumour volume. The dose planning is 
performed based on clips that mark the distal and proximal boarders of the 
tumour and prescribed at 10 mm from the applicator centre. By introducing 3D 
imaging, the tumour volume can be visualised. DVH parameters can also be 
obtained and the dose coverage to the tumour and organs at risk can be 
evaluated. In the DVH parameters for the oesophageal tumour presented in Table 
7 an under-dosage of about 30 % of the tumour volume was obtained when the 
dose was prescribed at 10 mm from the applicator centre. A clear benefit with 
manual dose planning based on dose coverage to the tumour was thus noted for 
this patient. Obtaining inadequate dose coverage to the tumour is not surprising 
since tumours are generally different in shapes; therefore, it is essential that the 
tumour volume should be taken into consideration for dose planning.  Improving 
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the tumour coverage could potentially lead to better treatment results and better 
patient comfort/quality of life. 
 
To the author’s knowledge, this is one of the first clinical brachytherapy of 
oesophageal cancer utilizing 3D imaging. To date, no information regarding 
DVH recommendations and constraints to the target volume or the organs at risk 
have been published. Future studies are thus needed for DVH recommendations 
and constraints to be determined. 
 
For further development of this methodology, collaborations have been made 
with the University Medical Center in Utrecht. As for today, no patients with 
oesophageal cancer have yet received treatment with MR as an imaging 
technique for dose planning in Utrecht. However, a study protocol has been 
carried out. 
  
5.5 Dose delivery 	  
Before MR-based brachytherapy can be delivered uncertainties regarding the 
dose delivery needs to be further investigated. One uncertainty is the movement 
of the applicator from the moment the MR imaging is performed until the dose is 
delivered. The distance from the applicator tip and the tumour is of great 
importance since the dose planning is based on this distance. While the clips can 
be visualised on an MR image, an x-ray image can be used as a reference image 
to ensure correct positing. By inserting a marker wire in the applicator, the 
distance from the first dwell position and the tumour can be visualised on an x-
ray image and an adjustment can then be made to correlate to the MR planning 
images. Moreover, margins can be added in the cranio-caudal direction to 
compensate for uncertainties. Further studies are needed to ensure a safe and 
accurate dose delivery.  	  
5.6 Dose and fractional schedule 
 
The optimal dose and fractional schedule for oesophageal cancer have yet to be 
reached. Studies with different dose and fractional schedules have been reviewed 
and summarised in section 2.4. By calculating the EQD2 and by studying the 
point where the dose was prescribed and the treatment results, fractional and 
dose schedules for curative and palliative treatments have been determined for 
this clinic. For manual dose planning, the OARs can receive high doses due to 
improved dose coverage to the tumour volume compared to when the dose is 
prescribed at a specific distance. Therefore, a consideration between the dose to 
the tumour volume and the OARs has to be made if the dose to the adjacent 
organs is considered to be too high.  
 
In summary, the ordinated dose is dependent on the patient’s health condition 
and the tumour size and location. In palliative treatments the secondary effects 
on the OARs is of less importance.   
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6. Conclusion  
 
In this study, a new methodology utilising MR for treatment of oesophageal 
cancer with brachytherapy has been investigated. The major benefit with MR 
based brachytherapy is the improved tumour visualisation, manifesting DVH 
parameters enabling dose coverage of the tumour. The next step is to construct 
clinical studies to determine dose-volume recommendations and constraints to 
the tumour and organs at risk based on this methodology. 
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